Structure-Function Relationships, Pharmacokinetics, and Potency of Orally and Parenterally Administered Progestogens

Treatment of the Postmenopausal Woman: Basic and Clinical Aspects, Third Edition

Volumn , Issue , 2007, Pages 779-798

  Stanczyk, Frank Z ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85148807404     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369443-0/50067-3     Document Type: Chapter

References (76)

1. FZ Stanczyk and MR Henzl (2001) Use of the name “progestin”. Contraception 64 1-2.
2. Position Statement, Role of progestogen in hormone therapy for post-menopausal women: position statement of the North American Meno-pause Society. Menopause 10 113-132.
3. MR Henzl (1986) Contraceptive hormones and their clinical use. Yen SSC, Jaffe RE (Eds) Reproductive endocrinology, physiology, pathophysiology, and clinical management Philadelphia: W.B. Saunders 643-682.
4. FZ Stanczyk (1996) Introduction: structure-function relationships, metabolism, pharmacokinetics and potency of progestins. Drugs Today 32 1-14.
5. FZ Stanczyk (2002) Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception. Rev Endocr Metabol Disord 3 211-224.
6. FZ Stanczyk (2003) All progestins are not created equal. Steroids 68 879-890.
7. FZ Stanczyk and S Roy (1990) Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids. Contraception ,42 67-96.
8. RA Edgren and FZ Stanczyk (1999) Nomenclature of the gonane progestins. Contraception 60 313.
9. FZ Stanczyk (2000) Pharmacokinetics of progesterone administered orally and parenterally. Sitruk-Ware R, Mishell DR, Jr (Eds) Progestins and anti-progestins in clinical practice New York: Marcel-Dekker 393-400.
10. JA Simon, DE Robinson, MC Andrews, et al. (1993) The absorption of oral micronized progesterone: the effect of food, dose proportionality, and comparison with intramuscular progesterone. Fer til Steril 60 26-33.
11. ML Padwick, J Endacott, C Matson and MI Whitehead (1986) Absorption and metabolism of oral progesterone when administered twice daily. Fertil S/mY 46 402-407.
12. R Sitruk-Ware (2000) Progestins in hormonal replacement therapy and prevention of endometrial disease. Sitruk-Ware R, Mishell DR, Jr (Eds) Progestins and anti-progestins in clinical practice New York: Marcel Dekker 269-287.
13. M Hiroi, FZ Stanczyk, U Goebelsmann, et al. (1975) Radioimmunoassay of serum medroxyprogesterone acetate (Provera) in women following oral and intravaginal administration. Steroids 26 373-386.
14. L-O Svensson, SH Johnson and S-E Olsson (1994) Plasma concentrations of medroxyprogesterone acetate , estradiol estrone following oral ad-ministration of Klimaxil , Trisequence/Provera and Divina. A random. Maturitas 18 229-238.
15. M Mathrubutham and K Fotherby (1981) Medroxyprogesterone acetate in hu-man serum. J Steroid Biochem 14 783-786.
16. A Victor and ED Johansson (1976) Pharmacokinetic observations on medroxypro-gesterone acetate administered orally and intravaginally. Contraception 14 319-329.
17. FZ Stanczyk, EJ Mroszczak, T Ling, et al. (1983) Plasma levels and pharma-cokinetics of norethindrone and ethinylestradiol administered in solu-tion and as tablets to women. Contraception 28 241-251.
18. V Odlind, E Weiner, A Victor and EDB Johansson (1979) Plasma levels of nor-ethindrone after single oral dose administration of norethindrone and lynestrenol. Clin Endocrinol 10 29-38.
19. DJ Back, AM Brackenridge, FE Crawford, et al. (1978) Kinetics of norethin-drone in women. II. Single-dose kinetics. Clin Pharmacol Ther 24 448-453.
20. GL Hammond, PL Lahteenmaki, T Luukkainen, et al. (1982) Distribution and percentages of non-protein bound contraceptive steroids in human serum. J Steroid Biochem 17 375-380.
21. W Kuhnz, A Huener, M Humpel, W Scifert and K Michaelis (1997) In vivo conversion of norethisterone and norethisterone acetate to ethinyl es-tradiol in postmenopausal women. Contraception 56 379-385.
22. Chu MC, Nakhuda GS, Zhang X, Stanczyk FZ, Lobo RA. Formation of ethinyl estradiol in women during treatment with norethindrone acetate. J Clin Endocrinol
23. M Humpel, H Wendr, G Dogs, et al. (1977) Intraindividual comparison of pharmacokinetic parameters of d-norgestrel, lynestrenol and cyproter-one acetate in 6 women. Contraception 16 199~215.
24. U Goebelsmann, D Hoffman, S Chiang and T Woutersz (1986) The relative bioavailability of levonorgestrel and ethinyl estradiol administered as a low-dose combination oral contraceptive. Contraception 34 341-351.
25. FZ Stanczyk, RA Lobo, ST Chiang and TB Woutersz (1990) Pharmacokinetic comparison of two triphasic oral contraceptive formulations containing levonorgestrel and ethinylestradiol. Contraception 41 39-53.
26. DJ Back, M Bates, AM Breckenridge, JM Hall and M Maclver (1981) Levo-norgestrel and ethinylestradiol in women-studies with Ovran and Ovranette. Contraception 23 229-239.
27. M Humpel, H Wendt, G Pommerenke, CHR Weib and U Speck (1978) Investi-gations of pharmacokinetics of levonorgestrel to specific consideration of a possible first pass effect in women. Contraception 17 207-220.
28. JL McGuire, A Phillips, DW Hahn, et al. (1990) Pharmacologic and pharma-cokinetic characteristics of norgestimate. Am J Obstet Gynecol 163 2127-2131.
29. W Kuhnz, H Blode and M Mahler (1993) Systemic availability of levonorgestrel after single oral administration of a norgestimate-containing oral con-traceptive to 12 women. Contraception 47 283-294.
30. T White, B.J.J.K. Ozel B Jain JK and FZ Stanczyk (2006) Effects of transdermal and oral steroidal contraceptives on estrogen-sensitive hepatic proteins, levo-norgestrel, serum-binding globulins, and C-reactive prot. Contraception 74 293-296.
31. L Viinikka (1978) Radioimmunoassay of a new progestogen, ORG 2969, and its metabolite. J Steroid Biochem 10 353-357.
32. L Viinikka (1979) Metabolism of a new synthetic progestogen, ORG 2969, by human liver in vitro. J Steroid Biochem 10 353-357.
33. HG Hasenack, AMG Bosch and K Kaar (1986) Serum levels of etonogestrel after oral administration of desogestrel and etonogestrel. Contraception 33 591-596.
34. J Hammerstein (1990) Prodrugs: advantage or disadvantage? Am J Obstet Gynecol 163 2198-2203.
35. DJ Back, SFM Grimmer, N Shenoy and MLE Orme (1987) Plasma concentra-tions of etonogestrel after oral administration of desogestrel and intra-venous administration of etonogestrel. Contraception 35 619-626.
36. M Orme, DJ Back, S Ward and S Green (1991) The pharmacokinetics of ethinyl estradiol in the presence and absence of gestodene and desogestrel. Contraception 43 305-316.
37. U Tauber, JW Tack and H Matthes (1989) Single dose pharmacokinetics of ges-todene in women after intravenous and oral administration. Contraception 40 461-479.
38. W Bergink, R Assendorp, L Koosterboer, et al. (1990) Serum pharmacokinet-ics of orally administered desogestrel and binding of contraceptive progestogens to sex hormone-binding globulin. Am J Obstet Gynecol 163 2132-2137.
39. H Kuhl, C Jung-Hoffman and F Heidt (1988) Serum levels of etonogestrel and SHBG during 12 cycles of treatment with 30 μg desogestrel. Contraception 38 381-390.
40. C Jung-Hoffman and H Kuhl (1989) Interaction with the pharmacokinetics of ethinyl estradiol and progestogens contained in oral contraceptives. Contraception 40 299-312.
41. W Kuhnz, M Pfeffer and G Al-Yacoub (1990) Protein binding of the contracep-tive steroids gestodene, 3-keto-desogestrel and ethinylestradiol in hu-man serum. J Steroid Biochem 35 313-318.
42. B Dusterberg, J-W Tack, W Krause and M Humpel (1987) Pharmacokinetics and biotransformation of gestodene in man. M Elstein,(Eds) Gestodene: development of a new gestodene-containing low-dose oral contraceptive London: Parthenon 35-44.
43. H Kuhl, C Jung-Hoffman and F Heidt (1988) Alterations in the serum levels of gestodene and SHBG during 12 cycles of treatment with 30 mg ethi-nyl estradiol and 75 mg gestodene. Contraception 38 477-486.
44. K Fotherby (1990) Potency and pharmacokinetics of gestagens. Contraception 41 533-550.
45. M Oettel, S Bervoas-Martin, W Elger, et al. (1995) A 19-norprogestin with-out a 17α-ethinyl group. I: Dienogest from a pharmacokinetic point of view. Drugs Today 31 499-516.
46. H Blode, W Wuttke, W Loock, G Röll and R Heithecker (2000) A 1-year phar-macokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers. Eur J Contracept Reprod Health Care 5 256-264.
47. R Krattenmacher (2000) Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 62 29-38.
48. SJ Nillius and EDB Johansson (1971) Plasma levels of progesterone after vaginal, rectal, or intramuscular administration of progesterone. Am J Obstet Gynecol 110 470-477.
49. FZ Stanczyk, E Gentzschein, BA Ary, et al. (1997) Urinary progesterone, pregnanediol, Use for monitoring progesterone treatment. J Reprod Med 42 216-222.
50. RA Miles, RJ Paulson and RA Lobo (1994) Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril 62 485-490.
51. FZ Stanczyk, R Paulson and S Roy (2005) Percutaneous administration of pro-gesterone: blood levels and endometrial protection. Menopause 12 232-237.
52. SM Bello, G Merzow, D Shoupe and FZ Stanczyk (1997) Administration of progesterone by use of percutaneous gel in postmenopausal women. Proceedings of the Annual Meeting of the Pacific Coast Fertility Society Indian Wells, CA, April 9-13
53. RA Edgren and FM Sturtevant (1976) Potencies of oral contraceptives. Am J Obstet Gynecol 125 1029-1038.
54. RA Edgren (1978) Progestational potency of oral contraceptives: a polemic. Int J Fertil 23 162-169.
55. RA Edgren (1979) Relative potencies of oral contraceptives. KS Moghissi,(Eds) Controversies to contraception Baltimore: Williams & Wilkins 1-19.
56. RA Edgren (1980) Progestins. JR Givens,(Eds) Clinical use of sex steroids Chicago: Year Book Medical 1-29.
57. M Juchem and K Pollow (1990) Binding of oral contraceptive progestogens to serum proteins and cytoplasmic receptor. Am J Obstet Gynecol 163 2171-2183.
58. A Phillips, DW Demarest, F Hahn, F Wong and JL McGuire (1990) Proges-tational and androgenic receptor binding affinities and in vivo ac-tivities of norgestimate and other progestins. Contraception 41 399-410.
59. M Juchem, E Pollow, W Elger, G Hoffman and V Mobus (1993) Receptor bind-ing of norgestimate—a new orally active synthetic progestational compound. Contraception 47 283-294.
60. MK Phail (1934) The assay of progestin. J Physiol 83 145-156.
61. RA Edgren (1994) Issues in animal pharmacology. JW Goldzieher, K Fotherby,(Eds) Pharmacology of the contraceptive steroids New York: Raven 81-97.
62. RB Greenblatt, EC Jungck and WE Barfield (1958) A new test of efficacy of progestational compounds. Ann NY Acad Sci 71 717.
63. GIM Swyer and V Little (1968) Clinical assessment of relative potency of progestogens. J Reprod Fertil Suppl 5 63-68.
64. LJ Dorflinger (1985) Relative potency of progestins used in oral contraceptives. Contraception 31 557-570.
65. MI Whitehead, PT Townsend, J Pryse-Davies, TA Ryder and RJB King (1981) Effects of estrogens and progestins on the biochemistry and mor-phology of the postmenopausal endometrium. N Engl J Med 305 1599.
66. MI Whitehead, PT Townsend, J Pryse-Davies, et al. (1982) Effects of various types and dosages of progestins on the postmenopausal endometrium. J Reprod Med 27 539.
67. G Lane, NC Siddle, TA Ryder, et al. (1983) Dose dependent effects of oral progesterone on the oestrogenised postmenopausal endometrium. Br Med J 287 1241.
68. M Whitehead, G Lane, N Siddle, P Townsend and R King (1983) Avoidance of endometrial hyperstimulation in estrogen-treated postmenopausal women. Semin Reprod Endocrinol 1 41.
69. MI Whitehead, NC Siddle, PT Townsend, G Lane and RJB King (1983) The use of progestins and progesterone in the treatment of climacteric and postmenopausal symptoms. CW Bardin, E Milgrom, Jarvis P Mauvais,(Eds) Progesterone and progestins New York: Raven 277.
70. G Lane, NC Siddle, TA Ryder, et al. (1986) Effects of dydrogesterone on the oestrogenized postmenopausal endometrium. Br J Obstet Gynaecol 93 55.
71. G Lane, NC Siddle, TA Ryder, et al. (1986) Is Provera the ideal progestin for addition to postmenopausal estrogen therapy? Fertil Steril 45 345.
72. RJB King and MI Whitehead (1986) Assessment of the potency of orally ad-ministered progestins in women. Fertility and Sterility 46 1062-1066.
73. AT Teichman (1990) Levonorgestrel. Stuart-George Thieme Verlag 43.
74. IH Thorneycroft, FZ Stanczyk, KD Bradshaw, et al. (1999) Effect of low-dose contraceptives on androgenic markers and acne. Contraception 60 255-262.
75. RC Jones and RA Edgren (1973) The effects of various steroids on the vaginal histology in the rat. Fertil Steril 24 284.
76. W Elger, S Beier, K Pollow, et al. (2003) Conception and pharmacodynamic profile of drospirenone. Steroids 68 891-905.